Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Psyadon Pharmaceuticals Inc.

Treating Tourette syndrome with a neuronal inhibitor

This article was originally published in Start Up

Executive Summary

No new drug has been developed for Tourette syndrome in more than 20 years. Almost all medications prescribed for the condition are given off-label, and none are particularly effective. News reported by Psyadon Pharmaceuticals Inc. in late July 2012 is encouraging to both the patient community and the start-up itself. Psyadon announced that an open-label Phase II study of its candidate ecopipam, which inhibits dopamine via the D1 receptor, was stopped after a planned interim data analysis because the data were strong enough to suggest the compound is conferring a genuine benefit.



Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts